Linvemastat (FP-020), a follow-on oral MMP-12 inhibitor, for which a Phase 1 study in healthy volunteers has been successfully completed, with development targeted in severe asthma, COPD and IBD.

Investigators from Foresee Pharmaceuticals Co. Ltd., Medical University of Vienna and Cleveland Clinic recently reported data on the effects of the matrix metalloproteinase-12 (MMP-12) inhibitor ...

Inhibiting MMP-12 with FP-020 attenuated macrophage infiltration, macrophage clustering, decreased fibrotic replacement, and reduced the number of activated fibroblasts. Mice with a conditional ...